BI 456906 vs Efinopegdutide
Head-to-head comparison of BI 456906 (BI 456906, glucagon-like peptide-1/glucagon receptor dual agonist) and Efinopegdutide (Efinopegdutide (HM12525A), long-acting glucagon-like peptide-1/glucagon receptor dual agonist) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | BI 456906 | Efinopegdutide |
|---|---|---|
| Category | Weight Management | Weight Management |
| Full Name | BI 456906, glucagon-like peptide-1/glucagon receptor dual agonist | Efinopegdutide (HM12525A), long-acting glucagon-like peptide-1/glucagon receptor dual agonist |
| Molecular Weight | N/A | N/A |
| Half-Life | Approximately 1 week | Approximately 1 week |
| Amino Acids | N/A | N/A |
| Typical Dose | Trial-dependent; weekly SC dosing | Trial-dependent; weekly SC dosing |
| Route | Subcutaneous | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 10 | 14 |
| Research Status | Clinical | Clinical |
BI 456906 Benefits
- ✓weight reduction
- ✓improved glucose control
- ✓lower liver-fat burden
- ✓enhanced satiety
Efinopegdutide Benefits
- ✓reduced body weight
- ✓improved insulin sensitivity
- ✓reduced liver fat
- ✓greater satiety
BI 456906 Dosing
once-weekly subcutaneous injection|stepwise titration|ongoing maintenance phase
Efinopegdutide Dosing
once-weekly subcutaneous injection|dose escalation during lead-in|maintenance dosing in trials
BI 456906 Side Effects
- ⚠nausea
- ⚠abdominal discomfort
- ⚠diarrhea
Efinopegdutide Side Effects
- ⚠nausea
- ⚠decreased appetite
- ⚠fatigue
Research Overview
BI 456906
Preclinical and early clinical research support meaningful metabolic effects with a tolerable safety profile. It remains investigational and is not commercially available.
Efinopegdutide
Human trials have shown meaningful weight loss and improvements in hepatic steatosis biomarkers. It remains a research compound with ongoing development in metabolic disease.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.